admin, Author at Atea Pharmaceuticals

Atea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership

Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience BOSTON, Mass., August 24, 2020 – Atea Pharmaceuticals,… Read More

Atea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.P., to the newly-created position of Chief Development Officer. Dr. Hammond will be responsible for overseeing Atea’s clinical development programs, specifically spearheading its development of AT-527 for the treatment of COVID-19. Read More

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, Redmile Group, Omega Funds, and funds and accounts managed by T. Rowe Price Associates, Inc. Read More

Atea Pharmaceuticals to present positive clinical data with AT-527 for the treatment of chronic Hepatitis C in patients with cirrhosis at The Liver Meeting® 2018

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today announced it will present positive data from its recently completed Phase IB/IIA trial of AT-527 in treatment-naïve HCV-infected patients, including HCV-infected patients with Child-Pugh A (CPA) cirrhosis. Read More

Atea Pharmaceuticals reports positive proof of concept clinical data with AT-527 for the treatment of chronic Hepatitis C

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced the appointment of Janet Hammond, M.D., Ph.D., Sc.M., F.C.P., to the newly-created position of Chief Development Officer. Dr. Hammond will be responsible for overseeing Atea’s clinical development programs, specifically spearheading its development of AT-527 for the treatment of COVID-19. Read More